These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6323087)

  • 1. Ranitidine disposition and systemic availability in hepatic cirrhosis.
    Smith IL; Ziemniak JA; Bernhard H; Eshelman FN; Martin LE; Schentag JJ
    Clin Pharmacol Ther; 1984 Apr; 35(4):487-94. PubMed ID: 6323087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
    Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
    Morichau-Beauchant M; Houin G; Mavier P; Alexandre C; Dhumeaux D
    Dig Dis Sci; 1986 Feb; 31(2):113-8. PubMed ID: 3943439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
    van Hecken AM; Tjandramaga TB; Mullie A; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1982 Aug; 14(2):195-200. PubMed ID: 6125204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of ranitidine in cirrhotic patients with or without ascites].
    Reymann JM; Richard MO; Bretagne JF; Allain H; Bentue-Ferrer D; D'Athis P; Van den Driessche J
    Therapie; 1986; 41(3):173-8. PubMed ID: 3750255
    [No Abstract]   [Full Text] [Related]  

  • 7. Ranitidine bioavailability and kinetics in normal male subjects.
    Garg DC; Weidler DJ; Eshelman FN
    Clin Pharmacol Ther; 1983 Apr; 33(4):445-52. PubMed ID: 6299642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranitidine kinetics in normal subjects.
    Chau NP; Zech PY; Pozet N; Hadj-Aissa A
    Clin Pharmacol Ther; 1982 Jun; 31(6):770-4. PubMed ID: 6280919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of ranitidine.
    Roberts CJ
    Clin Pharmacokinet; 1984; 9(3):211-21. PubMed ID: 6329583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.
    Young CJ; Daneshmend TK; Roberts CJ
    Gut; 1982 Oct; 23(10):819-23. PubMed ID: 6126422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of ranitidine in humans.
    Miller R
    J Pharm Sci; 1984 Oct; 73(10):1376-9. PubMed ID: 6094785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis.
    Comstock TJ; Sica DA; Harford A; Eshelman F
    Nephron; 1989; 52(1):15-9. PubMed ID: 2710266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
    Garg DC; Baltodano N; Perez GO; Oster JR; Jallad NS; Weidler DJ
    Pharmacology; 1985; 31(4):189-93. PubMed ID: 4059323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
    Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
    Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ranitidine on the disposition of orally and intravenously administered triazolam.
    Vanderveen RP; Jirak JL; Peters GR; Cox SR; Bombardt PA
    Clin Pharm; 1991 Jul; 10(7):539-43. PubMed ID: 1860302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses.
    Garg DC; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1985 Sep; 25(6):437-43. PubMed ID: 4056078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of rate controlled rectally administered ranitidine to male volunteers.
    De Bree H; De Boer AG
    Pharm Weekbl Sci; 1987 Jun; 9(3):179-82. PubMed ID: 3615159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
    Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone.
    Sirgo MA; Rocci ML; Ferguson RK; Eshelman FN; Vlasses PH
    Clin Pharmacol Ther; 1985 May; 37(5):534-8. PubMed ID: 3987177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.